Distribution of cytochrome P-450 4A and 4F isoforms along the nephron in mice

David E Stec1, Averia Flasch, Richard J Roman

  • 1Department of Physiology and Biophysics, Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center, Jackson 39216-4505, USA. dstec@physiology.umsmed.edu

Insights

This study identified multiple CYP4A and CYP4F enzyme isoforms in mouse kidney segments, revealing sex-specific differences in expression. This complexity suggests single-gene disruptions may not fully inhibit 20-HETE production in all renal areas.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biochemistry

Background:

  • 20-hydroxyeicosatetraenoic acid (20-HETE) plays a role in kidney function, regulating vascular tone and salt reabsorption.
  • Its production is linked to CYP4A and CYP4F enzymes, but specific isoforms in mouse kidney segments were unknown.

Purpose of the Study:

  • To identify CYP4A and CYP4F enzyme isoforms in microdissected mouse renal vascular and tubular segments.
  • To investigate potential sex-specific differences in the expression of these isoforms.

Main Methods:

  • RNA was isolated from microdissected renal blood vessels and nephron segments of male and female C57BL/6J mice.
  • Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect CYP4A and CYP4F isoform expression.

Main Results:

  • Multiple CYP4A and CYP4F isoforms were found in all analyzed renal segments.
  • Sex differences in isoform expression were observed in proximal tubules and glomeruli.
  • Specific CYP4A isoforms (4A10, -12, -14) and CYP4F isoforms (4F13, -14, -15, -16, -18) showed distinct patterns between sexes.

Conclusions:

  • Mouse renal vascular and tubular segments express a variety of CYP4A and CYP4F isoforms.
  • The presence of multiple isoforms suggests that targeting a single isoform may not be sufficient to abolish 20-HETE production.
  • Further research is needed to determine the specific roles of CYP4A versus CYP4F isoforms in 20-HETE production within these renal segments.

Related Concept Videos

Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...